Bigfoot Biomedical touted data last week at this year’s Diabetes Technology Meeting showing that results from a feasibility study evaluating the company’s automated insulin delivery system closely matched data gleaned from prospective modeling.
The company said it conducted extensive modeling to refine the technology’s algorithms prior to the start of its trial in 2016, Bigfoot said. Data collected from simulations closely predicted how Bigfoot’s automated insulin delivery system would perform when tested in a group of diverse patients.
“Bigfoot is heralding the future of artificial intelligence to accelerate the development and testing of drug delivery therapies,” president & CEO Jeffrey Brewer said in prepared remarks. “Our ability to model the physiology of insulin-requiring diabetes allows us to simulate months-long clinical trials consisting of thousands of subjects in mere minutes for a fraction of the cost.”
“People with insulin-requiring diabetes must constantly monitor their blood glucose levels, what and when they eat, and when and how they exercise in order to make calculations and decisions about using insulin,” Lane Desborough, Bigfoot’s chief engineer, added.
“Algorithms for automating insulin delivery must be safe and effective for a diverse group of people and account for significant variations in meals, stress, exercise, and illness. Our innovative virtual clinic provides critical insights into how our technology is anticipated to function in these real-world situations. The agreement between our predicted results and our study data validates and supports our use of modeling and simulation to hone our algorithms and predict clinical outcomes.”
Bigfoot is planning a pivotal trial for its system that is slated to launch in 2018 in the U.S.
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn